Company release 29th March 2022, 4:30 PM
BBS Oyj's Annual Report for 2021 has been published 29.3.2022. The Publication is attached to this release and can be found at https://www.bbs-artebone.fi/investors/financial-reports/
The Publication includes the English translation of the Annual Report and the Audited Financial Statements for 2021. The English translation of the Financial Statements for Financial Year 2021 is also available on company's website at https://www.bbs-artebone.fi/investors/financial-reports/.
More information:
Ilkka Kangasniemi, CEO
ilkka.kangasniemi@bbs-artebone.fi
+358 40 7080307
Distribution:
Nasdaq Helsinki Oy
Nasdaq Stockholm AB
Main Media
www.bbs-artebone.fi
BBS - Bioactive Bone Substitutes Plc
BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiologic biotech company. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic
surgery. The research and development in the field of medicine requires perseverance and courage to develop new things. We have over 20 years of expertise in this. Our operations are haracterised by top expertise, innovativeness and dedicated and committed employees. The
first product, ARTEBONE paste, is ready and the application process for the CE-marking enabling commercialization is in progress.
More information: www.bbs-artebone.fi
BBS-Bioactive Bone Substitutes Plc shares are listed on the Nasdaq First North Growth Market.
Attachments
- EN_Annual Report2021 (https://ml-eu.globenewswire.com/Resource/Download/14006ce2-02b8-40b3-a2ff-05204a2fac82)
- EN_BBS_Financial statement_2021 (https://ml-eu.globenewswire.com/Resource/Download/2d267f4a-0f86-4ead-a9bd-3c0446af7dd5)
